Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 32
Titolo Data di pubblicazione Autore(i) File
The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up. 1983 BERNENGO MG ;LISA F ;MEREGALLI M ;DE MATTEIS A ;ZINA G
T-cell subsets in melanoma patients evaluated by anti-T-cell monoclonal antibodies. 1983 BERNENGO MG ;LISA F ;PUIATTI P ;MEREGALLI M ;BERRUTO G ;ZINA G
The immunological profile of melanoma and the role of adjuvant thymostimulin therapy in stage I patients. 1984 BERNENGO MG ; DOVEIL GC ; LISA F; MEREGALLI M; NOVELLI M; ZINA G.
In vitro and in vivo effect of thymostimulin in melanoma patients. 1984 BERNENGO MG; LISA F; FRA P; MEREGALLI M; NOVELLI M; ZINA G.
Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma. 1984 BERNENGO MG ;LISA F ;MEREGALLI M ;DOVEIL GC
Functional properties in Sézary cells with an unusual phenotype. 1985 BERNENGO MG ;MEREGALLI M ;JEMMA C ;LISA F
[Cutaneous melanoma at the Turin Melanoma Center. I. Survival and correlation with clinical and histologic prognostic factors in 502 patients in stage I (1975-1985)] 1986 BERNENGO MG ;DOVEIL GC ;LISA F ;PIPPIONE M ;ALOI FG ;STUARDI C ;ZINA G
[Cutaneous melanoma at the Turin Melanoma Center. II. Risk of metastasis and free interval in relation to the clinical and histological prognostic factors in 502 patients in stage I (1975-1985)] 1987 BERNENGO MG ;DOVEIL GC ;LISA F ;STUARDI C ;ZINA G
Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study 1992 FIERRO MT; LISA F; M. NOVELLI; BERTERO M; BERNENGO MG
BANS: a discussion of the problem. 1992 BERNENGO MG ;REALI UM ;DOVEIL GC ;CAPPELLO N ;LISA F ;MORETTI S
Thymopentin in Sézary syndrome. 1992 M. BERNENGO; APPINO A; BERTERO M; NOVELLI M; FIERRO MT; DOVEIL GC; LISA F.
Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical application. 1993 BERNENGO MG; FIERRO MT; NOVELLI M; LISA F; APPINO A
KM-93 expression on peripheral blood lymphocytes (PBL) in inflammatory skin diseases, mycosis fungoides and Sézary syndrome. 1995 Quaglino P; Fierro MT; Savoia P; Novelli M; Lisa F; Bernengo MG
Clinical presentation and immunological features of an Italian ATL case 1995 FIERRO MT; SAVOIA P; NOVELLI M; GHISETTI V; LISA F; BERNENGO MG
Skin infiltrating lymphocyte flow-cytometric immunophenotyping: automated mechanical biopsy disaggregation and CD45 gating. 1996 Novelli M; Fierro MT; Lisa F; De Matteis A; Quaglino P; Savoia P; Verrone A; Cambieri I; Bernengo MG
Prognostic factors in Sezary sindrome 1997 Bernengo MG; Quaglino P; Novelli M; Cappello N; Doveil GC; Lisa F; De Matteis A; Fierro MT; Appino A.
Biological prognostic factors in advanced metastatic melanoma patients treated with chemoimmunotheraphy. 1997 Fierro MT; Quaglino P; Lisa F; Savoia P; Bernengo MG
Macrophage-mediated antitumor immunostimulation or immunosuppression modulates IL-2 therapeutic efficacy in advanced metastatic melanoma (MM) patients. 1997 Quaglino P; Lisa F; Cappello N; Zaccagna A; Bernengo MG.
Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. 1998 M.G. BERNENGO; P. QUAGLINO; M. NOVELLI; N. CAPPELLO; G.C. DOVEIL; F. LISA; A. DE MATTEIS; M.T. FIERRO; A. APPINO
Collagenase digestion and mechanical disaggregation as a method to extract and immunophenotype tumour lymphocytes in cutaneous T-cell lymphomas. 2000 M. NOVELLI; SAVOIA P; CAMBIERI I; PONTI R; COMESSATTI A; LISA F; BERNENGO MG
Mostrati risultati da 1 a 20 di 32
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile